Jiangsu Hengrui Pharmaceuticals Co., Ltd.
江蘇恒瑞醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1276)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to the disclosure requirements under Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

According to the relevant regulations of the People's Republic of China, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (the "**Company**") had published an announcement on the website of the Shanghai Stock Exchange (www.sse.com.cn). The following is a translation of the abovementioned announcement solely for reference only. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
江蘇恒瑞醫藥股份有限公司
Mr. Sun Piaoyang
Chairman

Shanghai, PRC
August 20, 2026

As at the date of this announcement, the Board comprises: (i) Mr. Sun Piaoyang, Mr. Dai Hongbin, Ms. Feng Ji, Mr. Zhang Lianshan, Mr. Jiang Frank Ningjun and Mr. Sun Jieping as executive Directors; (ii) Ms. Guo Congzhao as non-executive Director; and (iii) Mr. Lou Liguang, Mr. Zeng Qingsheng, Mr. Sun Jinyun and Mr. Chow Kyan Mervyn as independent non-executive Directors.

Stock code: 600276 Stock abbreviation: Hengrui Pharma No.: Lin 2026-128

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Announcement in Relation to the Approval for Drug Registration

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein.

Recently, a subsidiary of Jiangsu Hengrui Pharmaceuticals Co., Ltd. (江蘇恒瑞醫藥股份有限公司) (the "Company"), Chengdu Suncadia Medicine Co., Ltd. (成都盛迪醫藥有限公司), received a notice from the National Medical Products Administration (the "NMPA") approving the Company's self-developed Class 1 innovative drug Licancopan Fumarate (HRS-5965) Capsules for marketing. The relevant information is hereby announced as follows:

I. Basic Information of the Drug

Drug Name: Licancopan Fumarate Capsules

Dosage Form: Capsule

Strength: 25mg

Registration Category: Class 1 chemical drug

Acceptance No.: CXHS2600014

Prescription Drug/Over-the-Counter Drug: Prescription drug

Approved Indication: This product is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not previously received complement inhibitor therapy.

II. Other Information of the Drug

PNH is an acquired hemolytic disorder with a low incidence/prevalence and has

been included in the national “First Batch List of Rare Diseases”. It is characterized by the absence of complement regulatory proteins CD55 and CD59. Deficiency of CD59 results in uncontrolled formation of the membrane attack complex (MAC). Because PNH erythrocytes lack a nucleus and are chronically exposed to plasma complement, this leads to complement-mediated intravascular hemolysis. In addition, substantial C3b deposition on the surface of PNH erythrocytes can be recognized and cleared by macrophages in the liver and spleen, resulting in extravascular hemolysis[2, 3]. The amplification loop of the alternative complement pathway generates 80% of downstream complement activation products and represents a key step driving the occurrence and progression of hemolysis in PNH[4]. Dual hemolysis may lead to a series of clinical manifestations, including anemia, fatigue, thrombosis, and organ damage[2, 5]. Although C5 complement inhibitors have advanced PNH treatment by blocking the terminal complement pathway[6], even when used as initial therapy, 25% to 50% of patients continue to experience extravascular hemolysis. Approximately 74% of patients are troubled by fatigue, and only 21.3% of patients achieve complete hematologic response (defined as transfusion independence and absence of anemia)[1, 7, 8].

Licancopan Fumarate Capsules are a complement factor B inhibitor. As a proximal complement inhibitor targeting the alternative complement pathway, it inhibits abnormal activation of the alternative pathway and the complement amplification cycle. Mechanistically, it concurrently inhibits intravascular hemolysis and extravascular hemolysis and increases hemoglobin levels. For this indication, a product with the same target has already been approved in China, namely Novartis’ iptacopan hydrochloride capsules (Fabhalta®), approved for marketing in 2024. Lanoracopan hydrochloride tablets (Yishining®) from Createrna and ciprocopan succinate tablets (Youkepan®) from Haisco were approved for marketing in 2026. Based on a search of the EvaluatePharma database, Fabhalta® global sales in 2025 were approximately USD 505 million. In addition, the Marketing Authorization Application for this product for the treatment of PNH in patients who remain anemic after prior treatment with C5 complement inhibitors is also under review. To date, cumulative R&D investment for projects related

to Licancopan Fumarate Capsules is approximately RMB 277.5 million (unaudited).

III. Risk Warning

The Company places great importance on drug R&D, and strictly controls the quality and safety throughout the processes of drug R&D, manufacture, and sales. However, post-approval production and sales may be subject to uncertainties. Investors are kindly advised to make prudent decisions and pay attention to investment risks.

Notice is hereby given.

Board of Directors of Jiangsu Hengrui Pharmaceuticals Co., Ltd.

August 20, 2026

1. Bing Han, et al. Efficacy and safety of HRS-5965 versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria: a multicenter, randomized, open-label, active-controlled phase 3 trial. EHA 2026. Abstract: EHA-1896 Short: PF687.
2. Robert A. Brodsky. Paroxysmal nocturnal hemoglobinuria. Blood 2014. 124 (18): 2804-2811.
3. Jun Shi. Therapeutic goal and drug choice of paroxysmal nocturnal hemoglobinuria [J]. Chinese Journal of Practical Internal Medicine, 2025, 45(7): 548-553.
4. Harboe M, et al. The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin Exp Immunol. 2004 Dec; 138(3): 439-46.
5. Erythrocyte Disorders (Anemia) Group, Hematology Branch of the Chinese Medical Association. Guidelines for the diagnosis and management of paroxysmal nocturnal hemoglobinuria (2024) [J]. Chinese Journal of Hematology, 2024, 45(08): 727-737.
6. Jeff Szer. Extravascular hemolysis in PNH. Blood Adv 2025. 9 (19): 4977-4978.
7. Risitano AM, et al. Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT. Front. Immunol. 10:1157.
8. Dingli, D., et al. The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey. Ann Hematol 101, 251-263 (2022).